BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) have been given an average rating of “Moderate Buy” by the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $24.40.

BBOT has been the topic of a number of recent analyst reports. UBS Group lowered shares of BridgeBio Oncology Therapeutics to an “overweight” rating in a research report on Wednesday, July 8th. Oppenheimer initiated coverage on BridgeBio Oncology Therapeutics in a research report on Monday, June 22nd. They set an “outperform” rating and a $22.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a report on Thursday, June 18th. Canaccord Genuity Group started coverage on BridgeBio Oncology Therapeutics in a research note on Monday, May 11th. They set a “buy” rating and a $23.00 price target for the company. Finally, Wall Street Zen upgraded BridgeBio Oncology Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, July 18th.

BridgeBio Oncology Therapeutics Stock Up 2.5%

BBOT stock opened at $9.37 on Wednesday. BridgeBio Oncology Therapeutics has a twelve month low of $7.00 and a twelve month high of $14.87. The stock has a market capitalization of $751.19 million, a price-to-earnings ratio of -3.39 and a beta of 0.36. The firm’s fifty day simple moving average is $8.52 and its two-hundred day simple moving average is $8.90.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its earnings results on Tuesday, August 11th. The company reported ($705.20) earnings per share (EPS) for the quarter. As a group, equities research analysts expect that BridgeBio Oncology Therapeutics will post -2.79 EPS for the current year.

Institutional Trading of BridgeBio Oncology Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in BBOT. CIBC Private Wealth Group LLC bought a new stake in BridgeBio Oncology Therapeutics during the 4th quarter valued at about $63,000. XTX Topco Ltd grew its stake in BridgeBio Oncology Therapeutics by 22.4% in the 4th quarter. XTX Topco Ltd now owns 28,633 shares of the company’s stock worth $358,000 after acquiring an additional 5,249 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of BridgeBio Oncology Therapeutics during the fourth quarter worth approximately $107,000. Tema ETFs LLC raised its stake in shares of BridgeBio Oncology Therapeutics by 13.6% during the second quarter. Tema ETFs LLC now owns 93,339 shares of the company’s stock valued at $711,000 after acquiring an additional 11,167 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of BridgeBio Oncology Therapeutics during the fourth quarter valued at approximately $144,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.